{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-131786","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.452486+00:00","generated_at":"2026-05-15T08:26:14.097452+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PepGen reports positive Phase 2 FREEDOM2 data for PGN-EDODM1 in DM1; splicing correction 22.9% ex-outlier","bullets":["5 mg/kg cohort (n=8): mean splicing correction 7.3% overall, 22.9% excluding outlier; placebo 6.8%.","No serious adverse events; all TEAEs mild/moderate; nausea most common; no renal toxicity.","Middle finger vHOT showed improvement trend vs placebo worsening; returned to baseline at Week 16.","10 mg/kg cohort >50% enrolled; data expected 2H 2026; cash sufficient into 2H 2027.","Mean muscle PGN-EDODM1 concentration 158 ng/g in 5 of 6 treated patients (one pending)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-131786","json":"https://secwatch.observer/filing/0001193125-26-131786.json","markdown":"https://secwatch.observer/filing/0001193125-26-131786.md","text":"https://secwatch.observer/filing/0001193125-26-131786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000119312526131786/0001193125-26-131786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000119312526131786/pepg-20260330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:26:14.097452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}